Dean Miller

Managing Director, Novitas Capital

Dean Miller joined Novitas Capital in 1998, and is focused on early stage venture capital investments. He has over 19 years of experience working for and with both large and small companies. Dean is currently on the Board of Directors of Agile Therapeutics, Cellumen, ClickEquations, ImageTree and VIPdesk, and is an observer to the Board of Directors of GelMed Sciences, and Logical Therapeutics. He has led investments in and served as director or observer of Renal Solutions (acquired by Fresenius (NYSE: FMS)), Incurrent Solutions (acquired by Online Resources (NASDAQ: ORCC)) and LearnNow, Inc. (acquired by Edison Schools).

Previously, Dean served as the Chief Financial Officer of Adaptiv Learning Systems, a venture-backed start-up company that was spun out of the University of Pennsylvania’s Department of Psychology. Adaptiv Learning Systems provides resiliency training to corporations, educational institutions and a variety of other clients. At Adaptiv, he worked with the other Senior Management team members to analyze and execute financial, strategic, operational and marketing decisions.

Dean began his career at the Chubb Group of Insurance Companies, where he held a variety of management positions. While at Chubb, Dean was responsible for operations, financial management, technology management and internal consulting. In his last position at Chubb, he managed a regional department of 120 people with responsibility for over $250 million in revenue.

Dean is Chairman of Wharton Private Equity Partners, an international alumni organization (www.wpen.org) and serves on adjunct faculty at the Wharton School in the Department of Management. He also serves as a guest lecturer at the School of Engineering and Applied Science at the University of Pennsylvania. He is Chairman of the Mid-Atlantic Capital Alliance. Dean has served as a Commercial Reviewer for the National Science Foundation SBIR/STTR Biotechnology Grant Program.

He holds a Bachelor of Arts Degree in Business Administration and Psychology from Franklin and Marshall College; he has completed coursework in biotechnology at the University of California, San Diego; he has completed a Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation at the Tufts Center for the Study of Drug Development; and he graduated with distinction from the University of Pennsylvania’s Wharton School with an MBA in Private Equity.